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Summary
 
The Kaposi’s sarcoma–related herpesvirus (KSHV), also designated human herpesvirus 8, is the
presumed etiologic agent of Kaposi’s sarcoma and certain lymphomas. Although KSHV encodes
several chemokine homologues (viral macrophage inflammatory protein [vMIP]-I, -II, and -III),
only vMIP-II has been functionally characterized. We report here that vMIP-I is a specific agonist
for the CC chemokine receptor (CCR)8 that is preferentially expressed on Th2 T cells. Y3 cells
transfected with CCR8 produced a calcium flux in response to vMIP-I and responded vigorously
in in vitro chemotaxis assays. In competition binding experiments, the interaction of vMIP-I with
CCR8 was shown to be specific and of high affinity. In contrast to its agonist activity at CCR8,
vMIP-I did not interact with CCR5 or any of 11 other receptors examined. Furthermore, vMIP-I
was unable to inhibit CCR5-mediated HIV infection. These findings suggest that expression of
vMIP-I by KSHV may influence the Th1/Th2 balance of the host immune response.
Key words: chemokines • cell trafﬁcking • T helper cell type 1/T helper cell type 2 • 
AIDS/HIV • inﬂammation
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aposi’s sarcoma–associated herpesvirus (KSHV), also
designated human herpesvirus (HHV)-8, is a gamma-
herpesvirus linked to the etiology of Kaposi’s sarcoma (1).
KSHV has also been suggested to play a role in the pathology
of primary effusion lymphoma (2, 3). The genome of KSHV
has been shown to encode several chemokine-related pro-
teins, including a constitutively active chemokine receptor
and three viral chemokines, viral macrophage inflammatory
protein (vMIP)-I, vMIP-II, and vMIP-III, all belonging to
the CC or 
 
b
 
 family (4–7). Although two of these chemo-
kines (vMIP-I and vMIP-II) bear a high degree of identity to
one another (50% at the amino acid level; reference 4), only
vMIP-II has been characterized to any significant extent.
Thus, our understanding of the role that these chemokine-
related genes play in viral biology is incomplete.
There is no direct demonstration of vMIP-I interacting
with any receptor; however, Moore et al. reported that
transient expression of vMIP-I and CCR5 in CD4
 
1
 
 cat
kidney cells can block HIV infection (4), suggesting that
vMIP-I might interact with this receptor. In contrast to
these findings, a more recent report found no significant ef-
fect of exogenously added vMIP-I on HIV infection medi-
ated by CCR3, CCR5, or CXCR4 (8). However, vMIP-I
did inhibit macrophage-tropic HIV infection of PBMCs,
suggesting the possibility that another chemokine receptor
might mediate HIV entry into these cells (8).
 
Materials and Methods
 
Cell Lines.
 
CCR2, CCR6, CCR7, and CCR9 were stably
expressed in murine BaF/3 cells (9) using pME18S-neo (CCR2,
6, 7) or a murine retroviral system (CCR9 [reference 10]),
whereas CCR3 (11), CCR8, and HCR/L-CCR (12, 13) were
stably expressed in rat Y3 cells using either pME18S-neo (CCR3,
CCR8) or the murine retroviral system (HCR/L-CCR). CCR5,
XCR1, GPR9-6, and STRL33 were stably expressed in human
embryonic kidney (HEK) 293 cells using either pcDNA3.1 or
pcDNA3.1/zeo(
 
1
 
) (Invitrogen). CXCR4 was analyzed as an en-
dogenously expressed receptor present in the BaF/3 pre-B cell
line. All lines were maintained in appropriate culture medium
(RPMI or DMEM/10% FCS/10 ng/ml IL-3 for BaF/3 cells).
Media for transfected cell lines also contained G418 (1 mg/ml) or
zeocin (0.25 mg/ml; GIBCO BRL) and were periodically tested
for their ability to flux calcium in response to known ligands.
 
Calcium Flux Assays.
 
BaF/3 cells were loaded with Fluo-3-AM
(Sigma Chemical Co.) in appropriate culture medium (RPMI or
DMEM/10% serum) for 1 h at 37
 
8
 
C, after which cells were
washed three times in flux buffer (HBSS/20 mM Hepes/0.1%
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BSA) and aliquoted into a 96-well black-wall plates at a density
of 10
 
5
 
 cells/well. HEK 293 and Y3 cells were plated at a density
of 5 
 
3
 
 10
 
4
 
 cells/well 1 d in advance of assaying, loaded for 1 h in
culture medium as above and washed four times. All plates were
pre-coated with poly-
 
l
 
-lysine. Calcium flux was measured in all
96 wells simultaneously and in real time using a Fluorescent Im-
aging Plate Reader (FLIPR; Molecular Devices) and data was ex-
pressed as fluorescence units versus time. Chemokines were ob-
tained commercially (R&D Systems or Peprotech) or produced
by DNAX/Schering-Plough.
 
Assays for Chemotaxis and HIV Infection.
 
Chemotaxis was
assayed in a 48-well microchamber (Neuroprobe) as previously
described (14) using polycarbonate porous membranes (5-
 
m
 
m
pore size). Assays were conducted over a 1-h period and cells
were counted in an automated fashion on a Macintosh computer
using the public domain NIH Image program (developed at the
U.S. National Institutes of Health and available at http://
rsb.info.nih.gov/nih-image/). Five high power (400
 
3
 
) fields
were counted for each of the duplicate wells at a stated concen-
tration.
For HIV infection assays, pseudotyped virus was used in a sin-
gle cycle infection assay and infectivity was monitored as a mea-
sure of luciferase activity according to previously published meth-
ods (15). Pseudotyped HIV-1 stock was prepared by cotransfecting
HEK 293T cells with the envelope-deficient pNL4-3-luc-E
 
2
 
R
 
2
 
construct and a plasmid encoding the ADA envelope glycopro-
tein (pADAenv). 48–72 h after transfection, media was harvested,
filtered (0.22 
 
m
 
m), aliquoted, and stored at 
 
2
 
80
 
8
 
C. Pseudotyped
virus was added to HEK 293T cells that were transiently trans-
fected with CD4 alone or CD4 and CCR5. After a 4-d incuba-
tion at 37
 
8
 
C, cells were washed with PBS and lysed in reporter
lysis buffer (Promega). Lysates were assayed for luciferase activity
according to the instructions of the manufacturer. For inhibition,
chemokines were added at 100 nM at the same time as virus.
 
I-309/CCR8 Binding Assay.
 
CCR8-Y3 cells (1D-21, described
above) were resuspended in binding buffer (125 mM NaCl, 25
mM Hepes, 1 mM CaCl
 
2
 
, 5 mM MgCl
 
2
 
, and 0.5% BSA, pH 7.0;
200,000 cells in 200 
 
m
 
l) with 0.1 nM 
 
125
 
I-labeled I-309 (100,000
cpm). Unlabeled vMip-I and I-309 were included as competitors
where indicated. Reactions were incubated at room temperature
for 3–5 h, harvested (Unifilter-96 Harvester; Packard Instrument
Co.) onto 96-well GF/C filter plates (Packard Instrument Co.),
and washed with 4
 
8
 
C binding buffer containing 500 mM NaCl.
The filter plates were dried at room temperature overnight, scin-
tillation cocktail (Microscint-0; Packard Instrument Co.) was
added, and plates were counted (Topcount HTS; Packard Instru-
ment Co.). Data was analyzed by nonlinear regression (GraphPad
Prism; GraphPad Software, Inc.) and is expressed as the average
of triplicates (
 
6 
 
SD).
 
Results
 
Identification of CCR8 as a Specific Host-encoded Receptor
for vMIP-I.
 
To identify a host-encoded receptor(s) for
vMIP-I, we screened cell lines stably transfected with known
or suspected chemokine receptors for calcium flux in re-
sponse to vMIP-I and other chemokines. Among these cell
lines we found only CCR8-Y3 cells to be highly respon-
sive to vMIP-I (Fig. 1 A). These same cells also responded
to I-309 (Fig. 1 A), a confirmed human ligand for CCR8
(16–19), but not to any of 39 other chemokines tested (see
legend to Fig. 1). The calcium response to vMIP-I was
dose dependent and observable at picomolar concentrations
(Fig. 2 B). Prior incubation of CCR8-Y3 cells with vMIP-I
also decreased subsequent signaling to I-309 in a dose-depen-
dent manner (Fig. 2 C). Similarly, I-309 stimulation reduced
subsequent signaling to vMIP-I (Fig. 2 C). At the lowest
dose examined (0.01 nM first agonist), a slight enhancement
of signaling was observed when the second agonist was
added. 12 other receptors tested (CCR2, CCR3, CCR5,
CCR6, CCR7, CCR9, CXCR3, CXCR4, XCR1,
GPR9-6, STRL33, and HCR/L-CCR) failed to respond
Figure 1. Calcium flux of CCR8-Y3 and CCR5-293 cells in response
to various chemokines. (A) Various chemokines were used at concentra-
tions ranging from 10 to 50 nM to induce a calcium flux in Y3-CCR8
cells. Chemokines tested included MCP-1, MCP-2, MCP-3, MCP-4,
mMCP-5, eotaxin, MIP-1a, MIP-1b, DC-CK-1, RANTES, HCC-1,
mMIP-1g, m6Ckine, BCA-1, MIP-3a, MIP-3b, 6Ckine, fractalkine
(soluble domain), TARC, MDC, MIP-4, mC10, I-309, TECK, Mig, IP-
10, vMIP-I, SDF-1a, SDF-1b, IL-8, mJE, Gro-a, ENA-78, mTECK,
mLptn, NAP-2, mGCP-2, mLIX, and mMIP-2. Only positive responses
are shown as calcium flux (units) versus time and a vehicle control is indi-
cated. (B) Dose–response of CCR8-Y3 cells to vMIP-I. CCR8-Y3 cells
were stimulated with vMIP-I in a range of 1 mM–100 pM. A vehicle
control is indicated. Each curve shown is the average of duplicate wells
for each dose (SD did not exceed 10% of peak height). (C) Dose-depen-
dent heterologous desensitization of I-309/vMIP-I signaling. CCR8-Y3
cells were exposed to increasing concentrations of an initial agonist, either
I-309 (h) or vMIP-I (s), for 3 min before a second stimulation with the
indicated chemokine at 10 nM. Preincubation in vehicle alone is indi-
cated (vehicle/I-309, d; vehicle/vMIP-I, j). Results are graphed as peak
response versus concentration of initial agonist. (D) The response of
CCR5-293 cells to a panel of chemokines. The peak response of CCR5-
293 cells to various chemokines is shown. The panel used was identical to
that used in A except for the addition of 100 nM RANTES. In addition,
vMIP-I was tested at 1 mM, 100 nM, and 10 nM. Only those chemokines
producing a response and a few selected negative controls are shown. 
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to either vMIP-I or I-309 with a calcium flux (data not
shown).
To characterize more fully the interaction between vMIP-I
and CCR8, we examined the ability of vMIP-I to compete
for 
 
125
 
I-labeled I-309 binding to CCR8-Y3 cells. As shown
in Fig. 2, vMIP-I competed successfully for I-309 binding to
CCR8-Y3 cells with a 
 
K
 
i
 
 of 4.68 
 
6 
 
0.44 nM, which was
somewhat higher (sevenfold) than the 
 
K
 
i
 
 observed for I-309
binding (0.65 
 
6 
 
0.17 nM). In saturation binding experi-
ments, I-309 bound to CCR8-Y3 cells with a 
 
K
 
d
 
 of 0.40 
 
6
 
0.23 nM (
 
n
 
 5 
 
5, data not shown). Interestingly the EC
 
50
 
 for
CCR8-Y3 cell calcium response was roughly equivalent for
vMIP-I and I-309 stimulation (
 
z
 
3.7 nM).
 
vMIP-I Does Not Antagonize CCR5 or CXCR4 Signal-
ing.
 
Since previous reports have suggested that vMIP-I
might interact with CCR5 (4), we examined CCR5–HEK
293 cells for a response to vMIP-I. These cells did not flux
calcium in response to vMIP-I, SDF-1
 
a
 
, or eotaxin, but
were responsive to monocyte chemoattractant protein
(MCP)-2, MIP-1
 
a
 
, MIP-1
 
b
 
, and RANTES (Fig. 1 D).
vMIP-II has been suggested to act as an agonist for CCR3
(8), yet antagonizes other receptors, including CCR5 (20).
Therefore, we examined whether vMIP-I could antago-
nize CCR5 signaling in response to its natural ligands.
Prior incubation of HEK 293–CCR5 cells with vMIP-I was
unable to antagonize subsequent responses to any of the
CCR5 ligands tested, even when present at 100-fold excess
amounts (data not shown). In addition, preincubation of
the other available receptor cell lines (as above) with vMIP-I
failed to inhibit subsequent signaling of these receptors in re-
sponse to their known ligands (data not shown). These data
suggest that, unlike vMIP-II, vMIP-I is not a broad-spec-
trum chemokine antagonist.
 
Biological Activity of vMIP-I.
 
To determine whether
vMIP-I binding to CCR8-Y3 cells could mediate directed
cell migration, we performed in vitro chemotaxis assays.
CCR8-Y3 cells responded vigorously to both vMIP-I and
I-309 (Fig. 3). This response shows the typical bell-shaped
curve previously observed in microchemotaxis assays with a
maximal in the range of 1–10 nM for both vMIP-I and
I-309. Background migration in this assay system was es-
sentially zero, with fewer than five cells/five high power
fields migrating in response to medium alone. These data
demonstrate that vMIP-I acts as a CCR8 agonist for chemo-
taxis as well as calcium flux.
Because our data indicate that vMIP-I does not interact
with CCR5, and because reports of the ability of vMIP-I
to inhibit HIV infection are contradictory, we examined
whether recombinant vMIP-I would block CCR5-medi-
ated HIV entry. To address this question we used ADA en-
velope pseudotyped HIV-1 in a luciferase-based viral entry
assay. HEK 293 cells transiently transfected with CD4
alone or CD4 and CCR5 were used as target cells. As ex-
pected, 293 cells transfected with CD4 alone did not per-
mit viral entry (Fig. 4), whereas cells transfected with both
CD4 and CCR5 were very efficient in allowing HIV en-
try. In contrast to the earlier results reported by Moore et al.
(1, 4), but in agreement with Boshoff et al. (8), we found
vMIP-I to have no detectable effect on CCR5-mediated
HIV infection (Fig. 4). In contrast, RANTES was effective
in blocking HIV infection (Fig. 4) of CD4/CCR5 double
transfectants. This finding is consistent with our observa-
tion that vMIP-I is neither an agonist nor antagonist for
CCR5 (Fig. 2).
 
Discussion
 
Viruses have efficiently usurped various host genes in or-
der to manipulate a variety of host-cell functions as well as to
modify the host immune response. Through what amounts
to in vivo recombinant genetics, virus-encoded molecules
have been selected to retain and improve those functions
that are advantageous to the virus, while abrogating those
functions that are not (e.g., vIL-10). KSHV encodes several
Figure 2. vMIP-I inhibits
125I-labeled I-309 binding to
CCR8. Competition binding of
recombinant I-309 (squares) or
vMIP-I (triangles) was assessed
on CCR8-Y3 intact cells. Kd for
I-309 5 0.65 6 0.17 nM (n 5 2)
and  Ki for vMIP-I 5 4.68 6
0.44 nM (n 5 2). Results are ex-
pressed as total counts versus log
concentration of competitor.
Figure 3. Chemotactic re-
sponse of CCR8-Y3 cells. The
chemotactic response of CCR8-
Y3 cells to either vMIP-I (e) or
I-309 (h) was measured in the
48-well microchemotaxis assay.
Chemokines were used at the in-
dicated concentrations and re-
sults are shown as number of
cells migrating/five high power
(4003) fields versus concentra-
tion of ligand. The results are
representative of three indepen-
dent experiments and each data
point is the average of duplicate wells. The range of counts for each con-
centration is indicated. Vehicle alone served as a negative control.
Figure 4. vMIP-I does not in-
hibit CCR5-mediated HIV infec-
tion. The ability of vMIP-I to in-
hibit entry of the ADA strain of
HIV was compared with that of
RANTES (positive control) and
TECK (negative control). HEK
293 cells were transiently trans-
fected with CD4 or CD41
CCR5 as indicated. Chemokines
were used at 100 nM. Results are
representative of two experi-
ments. Each bar is the mean of
duplicate or triplicate data points
and results are expressed as relative
light units; percentage of control
(CD41CCR5) is also noted. 
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molecules that specifically target the chemokine subsystem
of the immune response. We have provided the first func-
tional characterization of one of these molecules, vMIP-I.
The data presented here demonstrate that vMIP-I is a spe-
cific and potent agonist for the chemokine receptor CCR8,
which is known to be preferentially expressed on Th2 cells.
In addition we have addressed questions regarding the abil-
ity of vMIP-I to inhibit CCR5-mediated HIV infection.
Understanding the functional role of KSHV-encoded
chemokines may help elucidate the mechanisms underlying
the pathology of Kaposi’s sarcoma. One function of vMIP-I
and vMIP-II may be to influence the balance of the im-
mune response toward a Th2 phenotype. Several lines of
evidence support this hypothesis. Recently, CCR8 has
been shown to be preferentially expressed on human and
mouse Th2 cells and its natural ligand, I-309, attracts Th2-
polarized T cells in vitro with considerable vigor (21, 22).
Here, we have presented data that demonstrates KSHV-
encoded vMIP-I is an agonist for CCR8 and that CCR8-
transfected cells migrate vigorously in response to vMIP-I.
In addition, KSHV-encoded vMIP-II has been reported
recently to be chemotactic for CCR8-transfected Jurkat
cells as well as Th2-polarized T cells (23). vMIP-II is also
reported to interact with CCR3 (8), which is expressed on
at least a subset of Th2 cells (24–26). Furthermore, vMIP-II
is an antagonist for CCR5 and CXCR3 (20), which are
preferentially expressed on Th1 cells (24, 26–28). Finally,
Sozzani et al. have reported that CD4
 
1
 
 and CD8
 
1
 
 T cell
clones generated from the neoplastic skin of patients with
Kaposi’s sarcoma are more heavily skewed toward a type II
cytokine profile than are clones obtained from patients with
alopecia areata or atopic dermatitis (23).
Another potential role for the vMIP-I–CCR8 interac-
tion is in apoptosis. Van Snick et al. reported that I-309 and
its murine homologue TCA-3 can block dexamethasone-
mediated apoptosis of the BW5147 thymoma (29), suggest-
ing a role for CCR8 in mediating this event. As a CCR8
agonist, vMIP-I might be used by KSHV to prevent apop-
tosis of a CCR8
 
1
 
 cell population. Alternatively, vMIP-I
might be expressed in order to attract potential host cells
for newly produced virus.
An important aspect of KSHV pathology is the interac-
tion of this virus with HIV. vMIP-II is reported to inhibit
viral entry through CCR5, CXCR4, and CCR3 (8, 20).
The role of vMIP-I in this regard has been less clear. Using
CD4
 
1
 
/cat kidney cells transiently expressing both CCR5
and vMIP-I, Moore et al. demonstrated a reduction in the
ability of R5 HIV-1 strains M23 and SF162 to enter these
cells and express p24 versus cells expressing only CCR5
(4). In a subsequent report, Boshoff et al. reported no effect
of vMIP-I on HIV-1 entry/p24 expression in U87/CD4
cells stably expressing CCR5, CCR3, or CXCR4, although
vMIP-I did inhibit infection of PBMCs (8). In support of
these later findings, we were unable to observe a calcium flux
in response to vMIP-I in 293 cells stably expressing CCR5
(Fig. 1 D). vMIP-I was also unable to antagonize RANTES,
MIP-1
 
a
 
, or MIP-1
 
b
 
 signaling in these cells. Furthermore,
we did not observe any effect of vMIP-I on HIV infection
of 293 cells transiently expressing both CCR5 and CD4,
although RANTES was effective in abrogating viral entry
(Fig. 4).
It is possible that differences in experimental systems can
explain why neither our group nor Boshoff et al. was able
to observe inhibition of CCR5-mediated HIV. Another
possibility is that vMIP-I acts to inhibit HIV infection
through some mechanism other than direct inhibition of
binding. If this were true then a simple explanation would
be that this mechanism simply does not operate in receptor-
transfected 293 cells but is functional in cat kidney cells and
PBMCs. Alternatively, it is possible that vMIP-I, when ex-
pressed endogenously by cat kidney cells, is posttranslation-
ally processed in such a manner as to produce a chemokine
that does interact with CCR5. However, this seems less
likely, as Boshoff et al. used exogenously added recombi-
nant vMIP-I to inhibit HIV entry into PBMCs (8). If this
effect was mediated by CCR5, one would expect recombi-
nant vMIP-I to be effective in transfected 293 cells as well.
Given the results reported here, one obvious hypothesis
is that the HIV infection of PBMCs in these experiments
was mediated by CCR8, which has been reported to allow
entry of some strains of HIV, including the ADA strain
used for the experiments presented in this report (30, 31).
Indeed we investigated this possibility and have been con-
sistently unable to observe infection of CCR8/CD4-trans-
fected 293 cells by the ADA strain HIV, despite confirmed
expression of both CCR8 and CD4. In any case, questions
regarding the ability of vMIP-I to affect HIV pathology are
clearly of interest and deserve further investigation.
A great deal has been learned about KSHV in the past
few years. This virus, which appears to be the etiologic
agent of Kaposi’s sarcoma and primary effusion lymphoma
(2, 3), recently has also been linked to the development of
multiple myeloma (32). Expression of the KSHV G-pro-
tein–coupled receptor in rodent fibroblasts leads to a prolif-
erative phenotype, suggesting a role for this constitutively
active chemokine receptor in cellular transformation (5,
33). It has been reported that vMIP-I and vMIP-II are an-
giogenic (8), and that vMIP-II is a broad-spectrum chemo-
kine antagonist (20). Understanding the role of vMIP-I in
the context of these other molecules, particularly as a
CCR8 agonist, should shed further light on our under-
standing of KSHV and HIV pathogenesis as well as on the
role of chemokines in viral immunity.
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